PRESS RELEASE

Q1 2023 — Press release

Q1 2023PDF · 22 pages942 KB
FOR IMMEDIATE RELEASE
 2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and
adjusted operational growth of 7.6%*
 2023 First-Quarter basic loss per share of ($0.03) decreasing 101.6% due to a special one-time charge,
with adjusted earnings per share (EPS) of $2.68 increasing by 0.4%*
 Company is increasing 2023 full-year guidance midpoints for adjusted operational sales and adjusted
operational EPS
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter
2023. “Our first quarter results demonstrate strong performance across all three segments of our business and
reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the
Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with
exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”
OVERALL FINANCIAL RESULTS
Q1
($ in Millions, except EPS) 	2023 	2022 	% Change
Reported Sales 	$24,746 	$23,426 	5.6%
Net Earnings/(Loss) 	($68) 	$5,149 	(101.3)%
EPS (basic/diluted) 5 	($0.03) 	$1.93 	(101.6)%
Q1
Non-GAAP* ($ in Millions, except EPS) 	2023 	2022 	% Change
Operational Sales1,2 	9.0%
Adjusted Operational Sales1,3 	7.6%
Adjusted Net Earnings1,4 	$7,068 	$7,129 	(0.9)%
Adjusted EPS (diluted)1,4 	$2.68 	$2.67 	0.4%
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
5 Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive
Note: values may have been rounded

-- 1 of 22 --

REGIONAL SALES RESULTS
Q1 	% Change
($ in Millions) 	2023 	2022 	Reported Operational1,2 Currency Adjusted
Operational1,3
U.S. 	$12,517 	$11,414 	9.7% 	9.7 	- 	7.4
International 	12,229 	12,012 	1.8 	8.3 	(6.5) 	7.9
Worldwide 	$24,746 	$23,426 	5.6% 	9.0 	(3.4) 	7.6
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: Values may have been rounded
SEGMENT SALES RESULTS
Q1 	% Change
($ in Millions) 	2023 	2022 	Reported Operational1,2 Currency Adjusted
Operational1,3
Consumer Health 	$3,852 	$3,586 	7.4% 	11.3 	(3.9) 	11.3
Pharmaceutical 	13,413 	12,869 	4.2 	7.2 	(3.0) 	7.2
MedTech 	7,481 	6,971 	7.3 	11.0 	(3.7) 	6.4
Worldwide 	$24,746 	$23,426 	5.6% 	9.0 	(3.4) 	7.6
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: Values may have been rounded

-- 2 of 22 --

FIRST QUARTER 2023 SEGMENT COMMENTARY:
Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and
translational currency.
Consumer Health
Consumer Health worldwide adjusted operational sales increased 11.3%* largely driven by over-the-counter (OTC)
products. Major contributors to growth in OTC were TYLENOL and MOTRIN analgesics, upper respiratory products,
IMODIUM in digestive health products and international smoking cessation products. Additional contributors to
growth were NEUTROGENA and AVEENO in Skin Health/Beauty products and JOHNSON’s in Baby Care products.
Pharmaceutical
Pharmaceutical worldwide adjusted operational sales grew 7.2%*, driven by DARZALEX (daratumumab), a biologic
for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-
mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the
treatment of patients with prostate cancer, CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T
immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma, and XARELTO
(rivaroxaban), a direct oral anticoagulant. Also contributing to growth were sales of the Janssen COVID-19 Vaccine
(Ad26.COV2.S) for the prevention of the SARS-CoV-2 Virus. This growth was partially offset by declines in sales of
REMICADE (infliximab), a biologic approved for the treatment of several immune-mediated inflammatory diseases,
IMBRUVICA (ibrutinib), an oral, once daily therapy approved for use in treating certain B-cell malignancies, a type
of blood or lymph node cancer, and ZYTIGA (abiraterone acetate), an oral, once daily medication for use in
combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.
MedTech
MedTech worldwide adjusted operational sales grew 6.4%*, driven primarily by electrophysiology products in
Interventional Solutions, contact lenses in Vision, wound closure products in General Surgery, and knees in
Orthopaedics. MedTech worldwide operational sales grew 11.0%*, with the acquisition of Abiomed contributing
4.6%.
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports
on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news

-- 3 of 22 --

releases and information available in the Investors section of the company’s
website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and
www.LTLManagementInformation.com.
Regulatory
Janssen Receives Positive CHMP Opinion for AKEEGA (Niraparib and Abiraterone Acetate Dual
Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2
Gene-Mutated Metastatic Castration Resistant Prostate Cancer
Press
Release
Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking
Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-
Line Targeted Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with
BRCA Gene Mutations
Press
Release
Data
Release
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI (cilta-cel) as
Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Press
Release
Late Breaking Data on Pulmonary Vein Isolation with HELIOSTAR Balloon Ablation Catheter
Presented at AF Symposium 2023
Press
Release
First Look at Data on Biosense Webster’s Investigational Pulsed Field Ablation Platform
Presented at AF Symposium 2023
Press
Release
Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at
High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Press
Release
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder
Cancer Through Precision Medicine and Early Intervention
Press
Release
TREMFYA (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab
in In Vitro Studies
Press
Release
New STELARA (ustekinumab) Long-Term Data Support its Established Safety Profile in
Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
Press
Release
Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of
Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy
in Patients with Pulmonary Arterial Hypertension (PAH)
Press
Release
TREMFYA (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than
IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque
Psoriasis
Press
Release
New RYBREVANT (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety
in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Who Have Failed Prior Platinum-Based Chemotherapy
Press
Release
Other
Johnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11
to Equitably Resolve All Current and Future Talc Claims1
Press
Release
Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D Press
Release
Johnson & Johnson Names Dr. Paula A. Johnson, President of Wellesley College, to its Board of
Directors
Press
Release
Johnson & Johnson Announces Pricing of $7.75 Billion of Senior Notes Issued by Kenvue Inc. Press
Release
Janssen Provides Portfolio Update Press
Release
ERLEADA (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with
Once-Daily, Single-Tablet Option, Now Available in the U.S.1
Press
Release
1 Subsequent to the quarter

-- 4 of 22 --

FULL-YEAR 2023 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company
is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These
items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
($ in Billions, except EPS) 	April 2023 	January 2023
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point 4.5% – 5.5% / 5.0% 	3.5% – 4.5% / 4.0%
Operational Sales2,5/ Mid-point2,5
Change vs. Prior Year / Mid-point
$97.9B – $98.9B / $98.4B
5.5% – 6.5% / 6.0%
$96.9B – $97.9B / $97.4B
4.5% – 5.5% / 5.0%
Estimated Reported Sales3,5/ Mid-point3,5
Change vs. Prior Year / Mid-point
$97.9B – $98.9B / $98.4B
5.5% – 6.5% / 6.0%
$96.9B – $97.9B / $97.4B
4.5% – 5.5% / 5.0%
Adjusted Operational EPS (Diluted)2,4/ Mid-point2,4
Change vs. Prior Year / Mid-point
$10.50 – $10.60 / $10.55
3.5% – 4.5% / 4.0%
$10.40 – $10.60 / $10.50
2.5% – 4.5% / 3.5%
Adjusted EPS (Diluted)3,4 / Mid-point3,4
Change vs. Prior Year / Mid-point
$10.60 – $10.70 / $10.65
4.5% – 5.5% / 5.0%
$10.45 – $10.65 / $10.55
3.0% – 5.0% / 4.0%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 2023 = $1.08 and April 2023 = $1.10 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
5 Excludes COVID-19 Vaccine
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by
visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the
live webcast in the Investors section of the company's website at events-and-presentations.

-- 5 of 22 --

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of
life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our
reach and size for good. We strive to improve access and affordability, create healthier communities, and put a
healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and
ingenuity to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth”
excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net
earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding
after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be
considered replacements for, and should be read together with, the most comparable GAAP financial measures.
Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investors section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at
quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional
information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of
selected compounds in late stage development and a copy of today’s earnings call presentation can also be found
in the Investors section of the company's website at quarterly results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act
of 1995 regarding, among other things: future operating and financial performance, product development, market
position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The
reader is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &
Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency
exchange rate fluctuations; competition, including technological advances, new products and patents attained by

-- 6 of 22 --

competitors; challenges inherent in new product research and development, including uncertainty of clinical success
and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to
patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including
restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays,
internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory
action; significant adverse litigation or government action, including related to product liability claims; changes to
applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost
containment; changes in behavior and spending patterns of purchasers of health care products and services;
financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the
separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to
successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the
separation; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company.
A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s
Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned
“Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s
subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson
does not undertake to update any forward-looking statement as a result of new information or future events or
developments.
Press Contacts: 	Investor Contacts:
Tesia Williams 	Jessica Moore
media-relations@its.jnj.com 	investor-relations@its.jnj.com

-- 7 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2023 	2022 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,735	$ 	1,557 	11.4 % 	11.4 	-
International 	2,117 	2,029 	4.4 	11.3 	(6.9)
3,852 	3,586 	7.4 	11.3 	(3.9)
Pharmaceutical (1)
U.S. 	7,023 	6,632 	5.9 	5.9 	-
International 	6,390 	6,237 	2.4 	8.6 	(6.2)
13,413 	12,869 	4.2 	7.2 	(3.0)
Pharmaceutical excluding COVID-19 Vaccine (1)
U.S. 	7,023 	6,557 	7.1 	7.1 	-
International 	5,643 	5,855 	(3.6) 	2.4 	(6.0)
12,666 	12,412 	2.0 	4.9 	(2.9)
MedTech (1)
U.S. 	3,759 	3,225 	16.6 	16.6 	-
International 	3,722 	3,746 	(0.6) 	6.2 	(6.8)
7,481 	6,971 	7.3 	11.0 	(3.7)
U.S. 	12,517 	11,414 	9.7 	9.7 	-
International 	12,229 	12,012 	1.8 	8.3 	(6.5)
Worldwide 	24,746 	23,426 	5.6 	9.0 	(3.4)
U.S. 	12,517 	11,339 	10.4 	10.4 	-
International 	11,482 	11,630 	(1.3) 	5.2 	(6.5)
Worldwide excluding COVID-19 Vaccine (1)	
23,999	$ 	22,969 	4.5 % 	7.7 	(3.2)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales reconciliation schedule
FIRST QUARTER
Percent Change

-- 8 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	12,517	$ 	11,414 	9.7 % 	9.7 	-
Europe 	6,332 	6,024 	5.1 	10.0 	(4.9)
Western Hemisphere excluding U.S. 	1,587 	1,482 	7.1 	14.3 	(7.2)
Asia-Pacific, Africa 	4,310 	4,506 	(4.3) 	4.1 	(8.4)
International 	12,229 	12,012 	1.8 	8.3 	(6.5)
Worldwide 	24,746	$ 	23,426 	5.6 % 	9.0 	(3.4)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 9 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	24,746	$ 	100.0 	23,426	$ 	100.0 	5.6
Cost of products sold 	8,395 	33.9 	7,598 	32.4 	10.5
Gross Profit 	16,351 	66.1 	15,828 	67.6 	3.3
Selling, marketing and administrative expenses 	6,138 	24.8 	5,938 	25.4 	3.4
Research and development expense 	3,563 	14.4 	3,462 	14.8 	2.9
In-process research and development 	49 	0.2 	610 	2.6
Interest (income) expense, net 	(20) 	(0.1) 	(12) 	(0.1)
Other (income) expense, net 	7,228 	29.2 	(102) 	(0.4)
Restructuring 	130 	0.6 	70 	0.3
Earnings/(Loss) before provision for taxes on income 	(737) 	(3.0) 	5,862 	25.0 	(112.6)
Provision for/(Benefit from) taxes on income 	(669) 	(2.7) 	713 	3.0 	(193.8)
Net earnings/(Loss) 	(68)	$ 	(0.3) 	5,149	$ 	22.0 	(101.3)
Net earnings/(Loss) per share (Basic/Diluted)* 	(0.03)	$ 	1.93	$ 	(101.6)
Average shares outstanding (Basic/Diluted)* 	2,605.5 	2,666.5
Effective tax rate 	90.8 % 	12.2 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	8,468	$ 	34.2 	8,218	$ 	35.1 	3.0
Net earnings 	7,068	$ 	28.6 	7,129	$ 	30.4 	(0.9)
Net earnings per share (Diluted) 	2.68	$ 	2.67	$ 	0.4
Average shares outstanding (Diluted)** 	2,634.3 	2,666.5
Effective tax rate 	16.5 % 	13.3 %
* Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive.
** Difference of 28.8 shares due to anti-dilutive impact on net loss position.
(1) See Reconciliation of Non-GAAP Financial Measures.
FIRST QUARTER
2023 	2022

-- 10 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2023 	2022
Net Earnings/(Loss), after tax- as reported 	($68) 	$5,149
Pre-tax Adjustments
Litigation expense 	6,900 	-
Intangible Asset Amortization expense 	1,204 	1,108
COVID-19 Vaccine related costs 1 	444 	-
Consumer Health separation costs 	300 	102
Restructuring related 2 	130 	72
(Gains)/losses on securities 	72 	411
Medical Device Regulation 3 	64 	60
IPR&D 	49 	610
Acquisition, integration and divestiture related 	42 	-
Other 	- 	(7)
Tax Adjustments
Tax impact on special item adjustments 4 (2,057) 	(393)
Consumer Health separation tax related costs 	11 	96
Tax legislation and other tax related 	(23) 	(79)
Adjusted Net Earnings, after tax 	$7,068 	$7,129
Average shares outstanding (Diluted) 	2,634.3 	2,666.5
Adjusted net earnings per share (Diluted) 	$2.68 	$2.67
Operational adjusted net earnings per share (Diluted) 	$2.75
Notes:
1
2
3
4
First Quarter
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs
and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.
In the first quarter of 2023, the company completed a prioritization of its research and development (R&D) investment within the
Pharmaceutical segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of
certain programs including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, HIV and hepatitis. The
restructuring expenses of $130 million in the quarter include the termination of partnered and non-partnered program costs and asset
impairments.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax
special items in arriving at adjusted earnings.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered
products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of
currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the
adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has
excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss
used for making operating decisions and assessing performance which is expected to be completed during 2024.

-- 11 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	MedTech 	Total
WW As Reported 	7.4% 	4.2% 	7.3% 	5.6%
U.S. 	11.4% 	5.9% 	16.6% 	9.7%
International 	4.4% 	2.4% 	(0.6)% 	1.8%
WW Currency 	(3.9) 	(3.0) 	(3.7) 	(3.4)
U.S. 	- 	- 	- 	-
International 	(6.9) 	(6.2) 	(6.8) 	(6.5)
WW Operational 	11.3% 	7.2% 	11.0% 	9.0%
U.S. 	11.4% 	5.9% 	16.6% 	9.7%
International 	11.3% 	8.6% 	6.2% 	8.3%
Abiomed 	(4.6) 	(1.4)
U.S. 	(8.2) 	(2.3)
International 	(1.6) 	(0.5)
All Other Acquisitions and Divestitures 	0.0 	0.0 	0.0 	0.0
U.S. 	0.0 	0.0 	0.0 	0.0
International 	0.0 	0.2 	0.0 	0.1
WW Adjusted Operational 	11.3% 	7.2% 	6.4% 	7.6%
U.S. 	11.4% 	5.9% 	8.4% 	7.4%
International 	11.3% 	8.8% 	4.6% 	7.9%
Adjusted Operational Sales Growth
FIRST QUARTER 2023 ACTUAL vs. 2022 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2023 	2022 	Reported 	Operational (1) 	Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	745	$ 	670 	11.0% 	11.0% 	-
Intl 	897 	791 	13.5% 	19.8% 	-6.3%
WW 	1,642 	1,461 	12.4% 	15.8% 	-3.4%
SKIN HEALTH / BEAUTY
US 	617 	544 	13.4% 	13.4% 	-
Intl 	493 	468 	5.3% 	12.6% 	-7.3%
WW 	1,110 	1,012 	9.7% 	13.1% 	-3.4%
ORAL CARE
US 	159 	143 	11.6% 	11.6% 	-
Intl 	202 	223 	-9.6% 	-4.0% 	-5.6%
WW 	361 	366 	-1.3% 	2.1% 	-3.4%
BABY CARE
US 	96 	85 	13.0% 	13.0% 	-
Intl 	263 	270 	-2.8% 	4.5% 	-7.3%
WW 	359 	355 	1.0% 	6.5% 	-5.5%
WOMEN'S HEALTH
US 	3 	3 	1.8% 	1.8% 	-
Intl 	214 	224 	-4.9% 	4.1% 	-9.0%
WW 	217 	228 	-4.8% 	4.1% 	-8.9%
WOUND CARE / OTHER
US 	115 	112 	2.6% 	2.6% 	-
Intl 	49 	52 	-6.0% 	2.3% 	-8.3%
WW 	164 	164 	-0.1% 	2.5% 	-2.6%
TOTAL CONSUMER HEALTH
US 	1,735 	1,557 	11.4% 	11.4% 	-
Intl 	2,117 	2,029 	4.4% 	11.3% 	-6.9%
WW 	3,852	$ 	3,586 	7.4% 	11.3% 	-3.9%
See footnotes at end of schedule
% Change

-- 13 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
PHARMACEUTICAL SEGMENT (2,3) 	2023 	2022 	Reported 	Operational (1) 	Currency
IMMUNOLOGY
US 	2,448	$ 	2,501 	-2.1% 	-2.1% 	-
Intl 	1,664 	1,617 	2.9% 	9.7% 	-6.8%
WW 	4,112 	4,119 	-0.2% 	2.5% 	-2.7%
REMICADE
US 	276 	358 	-22.8% 	-22.8% 	-
US Exports (4) 	41 	80 	-48.8% 	-48.8% 	-
Intl 	170 	225 	-24.4% 	-20.0% 	-4.4%
WW 	487 	663 	-26.5% 	-25.0% 	-1.5%
SIMPONI / SIMPONI ARIA
US 	271 	287 	-5.6% 	-5.6% 	-
Intl 	266 	283 	-6.1% 	1.8% 	-7.9%
WW 	537 	571 	-5.8% 	-1.9% 	-3.9%
STELARA
US 	1,451 	1,379 	5.2% 	5.2% 	-
Intl 	993 	909 	9.3% 	16.2% 	-6.9%
WW 	2,444 	2,288 	6.8% 	9.6% 	-2.8%
TREMFYA
US 	406 	391 	3.9% 	3.9% 	-
Intl 	234 	199 	17.3% 	24.9% 	-7.6%
WW 	640 	590 	8.4% 	11.0% 	-2.6%
OTHER IMMUNOLOGY
US 	3 	6 	-51.2% 	-51.2% 	-
Intl 	0 	0 	- 	- 	-
WW 	3 	6 	-51.3% 	-51.3% 	0.0%
INFECTIOUS DISEASES
US 	392 	461 	-14.9% 	-14.9% 	-
Intl 	1,193 	836 	42.8% 	49.2% 	-6.4%
WW 	1,586 	1,297 	22.3% 	26.4% 	-4.1%
COVID-19 VACCINE
US 	0 	75 	* 	* 	-
Intl 	747 	382 	95.6% 	* 	-8.9%
WW 	747 	457 	63.4% 	70.8% 	-7.4%
EDURANT / rilpivirine
US 	9 	9 	-1.4% 	-1.4% 	-
Intl 	271 	239 	13.4% 	18.7% 	-5.3%
WW 	280 	248 	12.8% 	18.0% 	-5.2%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	378 	369 	2.5% 	2.5% 	-
Intl 	99 	132 	-25.2% 	-21.2% 	-4.0%
WW 	477 	501 	-4.8% 	-3.7% 	-1.1%
OTHER INFECTIOUS DISEASES
US 	5 	8 	-33.1% 	-33.1% 	-
Intl 	77 	83 	-7.6% 	-5.6% 	-2.0%
WW 	82 	91 	-9.8% 	-8.0% 	-1.8%
% Change

-- 14 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2023 	2022 	Reported 	Operational (1) 	Currency
NEUROSCIENCE
US 	978 	843 	16.0% 	16.0% 	-
Intl 	826 	898 	-8.1% 	-3.1% 	-5.0%
WW 	1,804 	1,741 	3.6% 	6.1% 	-2.5%
CONCERTA / Methylphenidate
US 	70 	35 	* 	* 	-
Intl 	136 	122 	11.4% 	20.2% 	-8.8%
WW 	206 	157 	31.4% 	38.2% 	-6.8%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	713 	661 	7.9% 	7.9% 	-
Intl 	331 	387 	-14.6% 	-8.9% 	-5.7%
WW 	1,044 	1,048 	-0.4% 	1.7% 	-2.1%
SPRAVATO
US 	111 	61 	82.4% 	82.4% 	-
Intl 	20 	9 	* 	* 	*
WW 	131 	70 	86.9% 	88.0% 	-1.1%
OTHER NEUROSCIENCE
US 	84 	86 	-3.5% 	-3.5% 	-
Intl 	339 	380 	-10.7% 	-7.6% 	-3.1%
WW 	423 	467 	-9.4% 	-6.9% 	-2.5%
ONCOLOGY
US 	1,889 	1,582 	19.4% 	19.4% 	-
Intl 	2,223 	2,369 	-6.1% 	-0.1% 	-6.0%
WW 	4,112 	3,950 	4.1% 	7.7% 	-3.6%
CARVYKTI
US 	70 	- 	* 	* 	-
Intl 	2 	- 	* 	* 	-
WW 	72 	- 	* 	* 	-
DARZALEX
US 	1,191 	953 	25.0% 	25.0% 	-
Intl 	1,072 	903 	18.8% 	26.4% 	-7.6%
WW 	2,264 	1,856 	22.0% 	25.7% 	-3.7%
ERLEADA
US 	249 	206 	21.2% 	21.2% 	-
Intl 	293 	194 	50.9% 	60.7% 	-9.8%
WW 	542 	400 	35.6% 	40.3% 	-4.7%
IMBRUVICA
US 	270 	370 	-27.1% 	-27.1% 	-
Intl 	557 	668 	-16.6% 	-11.7% 	-4.9%
WW 	827 	1,038 	-20.3% 	-17.2% 	-3.1%
ZYTIGA / abiraterone acetate
US 	16 	19 	-14.0% 	-14.0% 	-
Intl 	229 	520 	-56.0% 	-52.2% 	-3.8%
WW 	245 	539 	-54.5% 	-50.9% 	-3.6%
OTHER ONCOLOGY
US 	92 	34 	* 	* 	-
Intl 	70 	84 	-17.2% 	-12.1% 	-5.1%
WW 	162 	118 	37.4% 	41.0% 	-3.6%
% Change

-- 15 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2023 	2022 	Reported 	Operational (1) 	Currency
PULMONARY HYPERTENSION
US 	600 	572 	4.9% 	4.9% 	-
Intl 	272 	279 	-2.7% 	5.3% 	-8.0%
WW 	872 	852 	2.4% 	5.0% 	-2.6%
OPSUMIT
US 	273 	273 	-0.1% 	-0.1% 	-
Intl 	167 	170 	-1.6% 	6.1% 	-7.7%
WW 	440 	443 	-0.7% 	2.3% 	-3.0%
UPTRAVI
US 	304 	269 	13.1% 	13.1% 	-
Intl 	58 	56 	3.3% 	9.4% 	-6.1%
WW 	362 	325 	11.4% 	12.4% 	-1.0%
OTHER PULMONARY HYPERTENSION
US 	23 	30 	-22.4% 	-22.4% 	-
Intl 	47 	53 	-12.6% 	-1.8% 	-10.8%
WW 	70 	83 	-16.1% 	-9.3% 	-6.8%
CARDIOVASCULAR / METABOLISM / OTHER
US 	715 	672 	6.3% 	6.3% 	-
Intl 	212 	238 	-10.8% 	-6.3% 	-4.5%
WW 	927 	910 	1.8% 	3.0% 	-1.2%
XARELTO
US 	578 	508 	13.7% 	13.7% 	-
Intl 	- 	- 	- 	- 	-
WW 	578 	508 	13.7% 	13.7% 	-
OTHER
US 	137 	164 	-16.7% 	-16.7% 	-
Intl 	212 	238 	-10.8% 	-6.3% 	-4.5%
WW 	349 	402 	-13.2% 	-10.5% 	-2.7%
TOTAL PHARMACEUTICAL
US 	7,023 	6,632 	5.9% 	5.9% 	-
Intl 	6,390 	6,237 	2.4% 	8.6% 	-6.2%
WW 	13,413	$ 	12,869 	4.2% 	7.2% 	-3.0%
See footnotes at end of schedule
% Change

-- 16 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
MEDTECH SEGMENT (2,3) 	2023 	2022 	Reported 	Operational (1) 	Currency
INTERVENTIONAL SOLUTIONS
US 	863	$ 	494 	74.5% 	74.5% 	-
Intl 	640 	597 	7.1% 	14.9% 	-7.8%
WW 	1,503 	1,092 	37.6% 	41.9% 	-4.3%
ELECTROPHYSIOLOGY
US 	571 	470 	21.4% 	21.4% 	-
Intl 	522 	532 	-1.8% 	6.1% 	-7.9%
WW 	1,092 	1,002 	9.1% 	13.3% 	-4.2%
ABIOMED
US 	264 	- 	* 	* 	-
Intl 	60 	- 	* 	* 	-
WW 	324 	- 	* 	* 	-
OTHER INTERVENTIONAL SOLUTIONS
US 	28 	24 	17.4% 	17.4% 	-
Intl 	58 	65 	-11.7% 	-5.0% 	-6.7%
WW 	87 	90 	-3.9% 	1.1% 	-5.0%
ORTHOPAEDICS
US 	1,363 	1,289 	5.8% 	5.8% 	-
Intl 	881 	899 	-2.0% 	4.0% 	-6.0%
WW 	2,245 	2,188 	2.6% 	5.1% 	-2.5%
HIPS
US 	241 	225 	7.3% 	7.3% 	-
Intl 	149 	164 	-9.0% 	-3.6% 	-5.4%
WW 	390 	389 	0.4% 	2.7% 	-2.3%
KNEES
US 	226 	201 	12.4% 	12.4% 	-
Intl 	142 	138 	3.4% 	9.6% 	-6.2%
WW 	368 	339 	8.7% 	11.3% 	-2.6%
TRAUMA
US 	491 	475 	3.2% 	3.2% 	-
Intl 	267 	273 	-2.4% 	3.6% 	-6.0%
WW 	757 	748 	1.2% 	3.4% 	-2.2%
SPINE, SPORTS & OTHER
US 	406 	387 	4.7% 	4.7% 	-
Intl 	323 	324 	-0.3% 	5.9% 	-6.2%
WW 	729 	712 	2.4% 	5.2% 	-2.8%
% Change

-- 17 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2023 	2022 	Reported 	Operational (1) 	Currency
SURGERY
US 	975 	921 	5.9% 	5.9% 	-
Intl 	1,459 	1,513 	-3.6% 	3.1% 	-6.7%
WW 	2,434 	2,434 	0.0% 	4.1% 	-4.1%
ADVANCED
US 	444 	417 	6.5% 	6.5% 	-
Intl 	673 	729 	-7.6% 	-1.1% 	-6.5%
WW 	1,118 	1,146 	-2.5% 	1.6% 	-4.1%
GENERAL
US 	531 	504 	5.4% 	5.4% 	-
Intl 	785 	784 	0.2% 	7.0% 	-6.8%
WW 	1,316 	1,288 	2.2% 	6.4% 	-4.2%
VISION
US 	558 	521 	7.1% 	7.1% 	-
Intl 	743 	736 	0.8% 	8.0% 	-7.2%
WW 	1,300 	1,257 	3.4% 	7.6% 	-4.2%
CONTACT LENSES / OTHER
US 	444 	400 	11.1% 	11.1% 	-
Intl 	509 	511 	-0.3% 	7.9% 	-8.2%
WW 	953 	910 	4.7% 	9.3% 	-4.6%
SURGICAL
US 	114 	121 	-6.0% 	-6.0% 	-
Intl 	233 	226 	3.3% 	8.0% 	-4.7%
WW 	347 	347 	0.1% 	3.1% 	-3.0%
TOTAL MEDTECH
US 	3,759 	3,225 	16.6% 	16.6% 	-
Intl 	3,722 	3,746 	-0.6% 	6.2% 	-6.8%
WW 	7,481	$ 	6,971 	7.3% 	11.0% 	-3.7%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures; refer to supplemental sales schedules
(4) Reported as U.S. sales
% Change
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely

-- 18 of 22 --

2023 	2022 	Total 	Operations 	Currency
Pharmaceutical
U.S. 	7,023	$ 	6,632 	5.9 % 	5.9 	-
International 	6,390 	6,237 	2.4 	8.6 	(6.2)
Worldwide 	13,413 	12,869 	4.2 	7.2 	(3.0)
COVID-19 Vaccine
U.S. 	0 	75 	* 	* 	-
International 	747 	382 	95.6 	* 	(8.9)
Worldwide 	747 	457 	63.4 	70.8 	(7.4)
Pharmaceutical excluding COVID-19 Vaccine
U.S. 	7,023 	6,557 	7.1 	7.1 	-
International 	5,643 	5,855 	(3.6) 	2.4 	(6.0)
Worldwide 	12,666 	12,412 	2.0 	4.9 	(2.9)
Worldwide
U.S. 	12,517 	11,414 	9.7 	9.7 	-
International 	12,229 	12,012 	1.8 	8.3 	(6.5)
Worldwide 	24,746 	23,426 	5.6 	9.0 	(3.4)
COVID-19 Vaccine
U.S. 	0 	75 	* 	* 	-
International 	747 	382 	95.6 	* 	(8.9)
Worldwide 	747 	457 	63.4 	70.8 	(7.4)
Worldwide
U.S. 	12,517 	11,339 	10.4 	10.4 	-
International 	11,482 	11,630 	(1.3) 	5.2 	(6.5)
Worldwide excluding COVID-19 Vaccine 	23,999	$ 	22,969 	4.5 % 	7.7 	(3.2)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
FIRST QUARTER
Percent Change

-- 19 of 22 --

Full Year 	Q1 	Q2 	Q3 	Q4 	Full Year
PHARMACEUTICAL SEGMENT (1)
NEUROSCIENCE
SPRAVATO
US 	198 	61 	74 	88 	105 	328
INTL 	26 	9 	11 	12 	14 	46
WW 	224 	70 	85 	100 	119 	374
OTHER NEUROSCIENCE (2)
US 	427 	86 	93 	106 	91 	376
INTL 	1,647 	380 	341 	286 	351 	1,358
WW 	2,074 	467 	433 	393 	442 	1,734
ONCOLOGY
CARVYKTI
US 	- 	- 	24 	55 	54 	133
INTL 	- 	- 	- 	- 	- 	-
WW 	- 	- 	24 	55 	54 	133
OTHER ONCOLOGY
US 	110 	34 	33 	37 	52 	156
INTL 	458 	84 	72 	64 	63 	283
WW 	568 	118 	106 	100 	114 	438
CARDIOVASCULAR / METABOLISM / OTHER
OTHER (3)
US 	754 	164 	148 	147 	110 	569
INTL 	927 	238 	215 	198 	194 	845
WW 	1,682 	402 	363 	345 	304 	1,414
MEDTECH SEGMENT (1)
INTERVENTIONAL SOLUTIONS
ELECTROPHYSIOLOGY
US 	1,730 	470 	499 	520 	547 	2,036
INTL 	1,893 	532 	469 	453 	447 	1,901
WW 	3,623 	1,002 	968 	973 	994 	3,937
ABIOMED (4)
US 	- 	- 	- 	- 	31 	31
INTL 	- 	- 	- 	- 	- 	-
WW 	- 	- 	- 	- 	31 	31
OTHER INTERVENTIONAL SOLUTIONS
US 	106 	24 	26 	27 	25 	102
INTL 	242 	65 	56 	60 	48 	230
WW 	348 	90 	81 	87 	73 	332
Note: Columns and rows within tables may not add due to rounding
(1) Unaudited
(2) Other Neuroscience is inclusive of RISPERDAL CONSTA, which was previously disclosed separately
(3) Other is inclusive of INVOKANA, which was previously disclosed separately
(4) Acquired on December 22, 2022
Supplemental Sales Information
(Dollars in Millions)
Certain prior year amounts have been reclassified to
conform to current year product disclosures
2021 	2022 	2022

-- 20 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment 	$ 	776 	686 	4,444 	3,924 	1,445 	1,477 	(7,102) 	(123) 	(300) 	(102) 	(737) 	5,862
% to Sales 	20.1% 	19.1% 	33.1% 	30.5% 	19.3% 	21.2% 	-28.7% 	-0.5% 	-1.2% 	-0.4% 	-3.0% 	25.0%
Intangible asset amortization expense 	82 	94 	739 	760 	383 	254 	- 	- 	1,204 	1,108
In-process research and development 	- 	610 	49 	- 	- 	- 	49 	610
Litigation related 	6,900 	- 	- 	6,900 	-
COVID-19 Vaccine related costs 	- 	- 	444 	- 	- 	- 	- 	- 	- 	- 	444 	-
Loss/(gain) on securities 	- 	38 	394 	34 	17 	- 	- 	72 	411
Restructuring related 	14 	130 	(14) 	72 	- 	- 	130 	72
Acquisition, integration and divestiture related 	- 	- 	42 	- 	- 	- 	42 	-
Medical Device Regulation 	- 	- 	64 	60 	- 	- 	64 	60
Consumer Health separation costs 	- 	- 	- 	- 	300 	102 	300 	102
Other 	- 	- 	- 	(7) 	- 	- 	(7)
Adjusted Income Before Tax by Segment 	$ 	858 	794 	5,795 	5,674 	2,017 	1,880 	(202) 	(130) 	- 	- 	8,468 	8,218
% to Sales 	22.3% 	22.1% 	43.2% 	44.1% 	27.0% 	27.0% 	-0.8% 	-0.6% 	0.0% 	0.0% 	34.2% 	35.1%
Q1 YTD - Income Before Tax by Segment
Dollars in Millions
Consumer Health 	Pharmaceutical 	MedTech 	Unallocated 	Worldwide Total
Consumer Health
Separation Costs

-- 21 of 22 --

First Quarter 	Acquistion, integration 	First Quarter
April 2, 2023
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
and divestiture
related
Medical Device
Regulation 	Other
April 2, 2023
Non-GAAP
Cost of products sold 	8,395	$ 	(1,200) 	- 	(23) 	(206) 	(12) 	6,954
Selling, marketing and admin expenses 	6,138 	(7) 	(38) 	6,093
Research and development expense 	3,563 	(16) 	(34) 	(16) 	(2) 	3,495
Other (Income) / Expense 	7,228 	(4) 	(6,900) 	- 	(26) 	(72) 	(222) 	(285) 	- 	(281)
In-process research and development 	49 	(49) 	-
Interest (Income) / Expense 	(20) 	37 	17
Restructuring 	130 	(130) 	-
Provision for/(Benefit from) taxes on income 	(669) 	194 	1,622 	11 	32 	5 	16 	12 	105 	60 	(11) 	23 	- 	1,400
Net Earnings/(Loss) 	(68) 	1,010 	5,278 	38 	98 	37 	56 	52 	339 	240 	11 	(23) 	- 	7,068
First Quarter 	Acquistion, integration 	First Quarter
April 3, 2022
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
and divestiture
related
Medical Device
Regulation 	Other
April 3, 2022
Non-GAAP
Cost of products sold 	7,598	$ 	(1,108) 	(16) 	(22) 	6,452
Selling, marketing and admin expenses 	5,938 	(6) 	5,932
Research and development expense 	3,462 	(32) 	3,430
Other (Income) / Expense 	(102) 	- 	- 	14 	- 	(411) 	- 	(102) 	7 	(594)
In-process research and development 	610 	(610) 	-
Restructuring 	70 	(70) 	-
Provision for taxes on income 	713 	168 	(53) 	138 	12 	- 	96 	11 	- 	23 	(96) 	79 	(2) 	1,089
Net Earnings 	5,149 	940 	53 	472 	60 	- 	315 	49 	- 	79 	96 	(79) 	(5) 	7,129
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Consumer Health
separation tax
related costs
In-process
research and
development
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation costs
Tax legislation
and other tax
related

-- 22 of 22 --